Table 1.

Demographics, patient, and tumor characteristics of patients eligible for follow-up SPECT

Patient	Age (years)	Sex	Tumor diameter (mm)	1 month FU 111In-girentuximab-SPECT	MRI FU imaging at 1 month	FU imaging during further FU (modality)	FU duration (months)	Biopsy before ablation	Remarks
1	79	F	24	Negative	Negative	Negative (CT)	33	ccRCC	Allergic reaction on gadolinium-based contrast
2	71	F	23	Negative (high non-specific uptake outside ablated lesion)	Negative	Negative (MRI)	16	cc RCC	On hemodialysis due to diabetic nephropathy.
3	70	M	25	Negative	Negative	Negative (MRI)	1	ccRCC	Died 2 months after last FU imaging due to cause unrelated to RCC
4	82	F	30	Negative	Negative	Negative (MRI)	32	ccRCC
5	72	M	28	Negative	Negative	Negative (MRI)	33	Inconclusive	Previous contralateral nephrectomy and ipsilateral cryoablation for ccRCC
6	71	F	12	Negative	Negative	Negative (MRI)	30	Inconclusive	Previous radical nephrectomy and ipsilateral partial nephrectomy for ccRCC
7	79	M	32	Positive	Negative	Positive at 6 months FU (CT)	14	Not performed	Initial treatment for local control primary tumor after radiotherapy of single synchronous osseous metastasis (biopsy proven ccRCC). Died after 15 months FU due to progressive disease. Treated with sunitinib after treatment primary tumor
8	83	M	44	Negative	Negative	Negative (MRI)	17	ccRCC
9	58	M	30	Negative	Negative	Negative (CT)	15	ccRCC	Previous contralateral radical nephrectomy for ccRCC, known metastatic disease, Von Hippel Lindau, targeting for girentuximab proven on 89Zr-girentuximab SPECT7

FU follow-up; SPECT single photon emission computed tomography, ccRCC clear cell renal cell carcinoma